Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome.
about
Acute Kidney Injury in Patients with CirrhosisHepatorenal syndrome: Update on diagnosis and treatmentCreatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-AnalysisProtecting the Kidney in Liver Transplant Candidates: Practice-Based Recommendations From the American Society of Transplantation Liver and Intestine Community of Practice.Cirrhosis and its complications: evidence based treatment.Renal dysfunction in patients with cirrhosis: Where do we stand?Alcoholic hepatitis 2010: a clinician's guide to diagnosis and therapy.Renal dysfunction in cirrhosis.Therapeutic response to vasoconstrictors in hepatorenal syndrome parallels increase in mean arterial pressure: a pooled analysis of clinical trials.Hemodynamic phenotype of the failing Fontan in an adult population.Revision and update on clinical practice guideline for liver cirrhosis.Hepatorenal syndrome: the 8th International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group.Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: randomized clinical trial.Acute kidney injury in cirrhosis.Terlipressin in hepatorenal syndrome: a systematic review and meta-analysisManagement and treatment of patients with cirrhosis and portal hypertension: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program.Treatment of hepatorenal syndrome.Cardiovascular changes in cirrhosis: pathogenesis and clinical implications.Management of hepatorenal syndrome in patients with cirrhosis.Recent advances in our understanding of hepatorenal syndrome.Optimal management of hepatorenal syndrome in patients with cirrhosis.Management of hepatorenal syndrome.Sepsis-induced acute kidney injury in patients with cirrhosis.Prognosis of Acute Kidney Injury and Hepatorenal Syndrome in Patients with Cirrhosis: A Prospective Cohort Study.Keeping high model for end-stage liver disease score liver transplantation candidates alive.Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and OctreotideTherapeutic alternatives for the treatment of type 1 hepatorenal syndrome: A Delphi technique-based consensus.Treatment to improve acute kidney injury in cirrhosis.The Relationship between Renal Dysfunction and Abnormalities of the Immune System in Patients with Decompensated Cirrhosis.The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites.Midodrine for the weaning of vasopressor infusions.Diagnosis and therapy of ascites in liver cirrhosis.Kidneys in chronic liver diseases.Management and outcome in hepatorenal syndrome: need for renal replacement therapy in non-transplanted patients.Hepatorenal Acute Kidney Injury and the Importance of Raising Mean Arterial Pressure.
P2860
Q26775643-1833D9F7-8C25-4ED3-B441-EFF8A3CC7E9EQ26777608-50FFC7D7-005A-485F-8A65-A44E546BA710Q26795734-AF67F4A4-9342-49EF-8C69-5376F4C5DE64Q30251763-A4EF41A2-4781-484C-96D6-66517B757E3CQ33594931-80F2274B-E502-4167-BF05-F5AB06E8A06DQ34047665-1390AC6D-6937-4033-B1E7-299C3946B448Q34213719-042C66B3-F0F2-4FCE-8A88-AEA1D6A309C8Q35559713-1293B02A-19F1-4A0A-8C83-0F48AF868B37Q35654104-DCD7C75F-408A-4681-ADC6-819C93D0C22DQ35860896-C7915D4E-149D-47A9-9549-B4C43D59DE5FQ35890613-ABB4EE41-1343-42AD-97D1-CC7146459F2DQ36093575-8314B18B-DD5E-4E18-A60F-3D1AC789D27FQ36422621-7254852E-98A3-461C-818C-CF23344EBBDDQ37323711-5C775504-26F5-481B-A6A1-9DE543076BF5Q37438171-F9BF73C9-2FD2-4EDF-8ECA-B5016C8DD3A4Q37489472-B700036B-2FE0-42D2-A493-E40E170927DAQ37605883-3658920E-9379-4922-B673-BCB636C6B3DAQ37771146-D83580A3-3B11-4ED1-924A-81806DBBF79AQ37913980-8AD41CA0-B3C5-481E-A438-778EACF50D92Q38012022-1DB629DB-C980-470F-87B0-271A69949D2BQ38173738-2257178B-9204-4C87-BD77-EED21925FAEFQ38463841-AB9A2739-8D75-4D6B-94A6-6379F0550A4BQ38542536-0554E5C2-70CF-42F0-9339-8D33D9DB9A3DQ38565163-CBEBB1A5-1EC6-4B5F-A927-BC904B3B6F52Q38579840-41D852B8-0397-4D74-9F74-5CEF9F042B12Q38869934-B3671F03-96B9-49C1-93CE-CCFC4710F7EDQ38962412-1B9659F7-5BB2-45F3-8805-68A5E145DF01Q39029019-0142764F-65FB-4E13-8FFE-A09CEF795E7EQ39483855-CDE34CC9-D85F-4903-A9D1-6F52454131BAQ39773776-FEE4AE51-5AE8-47B5-A67B-BB447F38EF97Q39946093-4A3AB302-1FEF-4AB0-9CBE-9C2538AA690BQ42707608-860C8AA9-54F3-41CF-8A9C-552BDE922ADCQ43209206-6355065D-5B7B-4447-A529-259D0560FBCBQ47807373-6B147D26-D108-4740-88D7-535B9411E64DQ53662298-2D5F83C8-3BFB-43DD-B2B3-69640988DAAA
P2860
Octreotide/Midodrine therapy significantly improves renal function and 30-day survival in patients with type 1 hepatorenal syndrome.
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Octreotide/Midodrine therapy s ...... h type 1 hepatorenal syndrome.
@ast
Octreotide/Midodrine therapy s ...... h type 1 hepatorenal syndrome.
@en
Octreotide/Midodrine therapy s ...... h type 1 hepatorenal syndrome.
@nl
type
label
Octreotide/Midodrine therapy s ...... h type 1 hepatorenal syndrome.
@ast
Octreotide/Midodrine therapy s ...... h type 1 hepatorenal syndrome.
@en
Octreotide/Midodrine therapy s ...... h type 1 hepatorenal syndrome.
@nl
prefLabel
Octreotide/Midodrine therapy s ...... h type 1 hepatorenal syndrome.
@ast
Octreotide/Midodrine therapy s ...... h type 1 hepatorenal syndrome.
@en
Octreotide/Midodrine therapy s ...... h type 1 hepatorenal syndrome.
@nl
P2093
P1476
Octreotide/Midodrine therapy s ...... h type 1 hepatorenal syndrome.
@en
P2093
Bruce A Runyon
Eric Esrailian
Eugene R Pantangco
Namgyal L Kyulo
P2888
P304
P356
10.1007/S10620-006-9312-0
P577
2007-03-01T00:00:00Z
P6179
1027694936